<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700176</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2020-0280</org_study_id>
    <nct_id>NCT04700176</nct_id>
  </id_info>
  <brief_title>A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma</brief_title>
  <official_title>A Multi-Center Phase 2 Study of Daratumumab With Pomalidomide and Dexamethasone in Combination With All-Transretinoic Acid in Patients With Multiple Myeloma Previously Exposed to Daratumumab-Based Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hackensack Meridian Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hackensack Meridian Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and efficacy of the study drug daratumumab,&#xD;
      when given together with Pomalidomide, Dexamethasone, and All-Transretinoic Acid (ATRA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-institution phase II study of ATRA in combination with fixed dose&#xD;
      Daratumumab, Pomalidomide and Dex for a total of 33 patients in patients with relapsed&#xD;
      multiple myeloma who have progressed on the combination of Dara + Len + Dex. There will also&#xD;
      be an exploratory cohort with an additional 10 patients who have progressed on the&#xD;
      combination of Dara + Pom + Dex.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (Cohort A)</measure>
    <time_frame>12 Months</time_frame>
    <description>To determine the ORR of the combination of Dara + Pom + Dex + ATRA in patients progressing on Dara + Len + Dex (Cohort A)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>12 Months</time_frame>
    <description>Incidence of Adverse Events in the combination of Dara + Pom + Dex + ATRA using CTCAE V5 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (Cohort B)</measure>
    <time_frame>12 Months</time_frame>
    <description>To determine the ORR of the combination of Dara + Pom + Dex + ATRA in patients progressing on Dara + Pom + Dex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Stringent Complete Response</measure>
    <time_frame>12 Months</time_frame>
    <description>To determine the best stringent complete response (sCR)/CR/near CR (nCR) and &gt;/= very good partial response (VGPR) rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>12 Months</time_frame>
    <description>To define the toxicity using CTCAE V5 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease Evaluation</measure>
    <time_frame>12 Months</time_frame>
    <description>To evaluate the status of minimal residual disease (MRD) in patients who achieve sCR, CR, or nCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on Study (TOS)</measure>
    <time_frame>12 Months</time_frame>
    <description>Duration from start of study treatment to end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>12 Months</time_frame>
    <description>Duration from treatment response to progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Progression (TTP)</measure>
    <time_frame>12 Months</time_frame>
    <description>Duration from start of study treatment to progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>12 Months</time_frame>
    <description>Duration from start of study treatment to PD or death [regardless of cause], whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>12 Months</time_frame>
    <description>Duration from start of study treatment to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed or refractory multiple myeloma who have progressed on the combination of Dara + Len + Dex (Cohort A) to be treated with a combination of Dara + Pom + Dex + ATRA (All-Transretinoic Acid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed or refractory multiple myeloma who have progressed on the combination of Dara + Pom + Dex (Cohort B) to be treated with a combination of Dara + Pom + Dex + ATRA (All-Transretinoic Acid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>During 28-day treatment cycles, patients will receive Dara 16 mg/kg intravenously (IV) at their current dose upon enrollment onto the study depending on their cycle. They will receive Dara depending on the cycle they are in. If they are on cycles 1-2 then they will receive Dara 16 mg/kg IV on days 1,8,15,22; if they are on cycles 3-6 they will receive Dara 16 mg/kg on days 1 and 15; and if they are on cycle 7 or beyond they will receive Dara 16 mg/kg on day 1.</description>
    <arm_group_label>Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A)</arm_group_label>
    <arm_group_label>Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B)</arm_group_label>
    <other_name>Darzalex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Pomalidomide will be administered at the patient's currently tolerated dose (4,3, or 2 mg po daily) on days 1-21</description>
    <arm_group_label>Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A)</arm_group_label>
    <arm_group_label>Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B)</arm_group_label>
    <other_name>Pomalyst</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>All-trans retinoic acid</intervention_name>
    <description>ATRA will be administered in a divided dose of twice daily as an oral formulation at 45mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled Dara infusion. The last administration of ATRA will be given in the evening of the day that Dara was administered</description>
    <arm_group_label>Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A)</arm_group_label>
    <arm_group_label>Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B)</arm_group_label>
    <other_name>ATRA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone will be administered at 40 mg once weekly on days 1,8,15 for patients 75 years old and younger and at 20 mg once weekly on days 1,8,15 for patients older than 75.</description>
    <arm_group_label>Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A)</arm_group_label>
    <arm_group_label>Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Documented multiple myeloma&#xD;
&#xD;
          2. For cohort A, patients must have been previously exposed to Dara+Len+Dex and must have&#xD;
             achieved at least stable disease to this combination.&#xD;
&#xD;
          3. For cohort B, patients must have been exposed to Dara + Pom + Dex and must have&#xD;
             achieved at least stable disease to this combination.&#xD;
&#xD;
          4. Histologically confirmed and relapsed multiple myeloma with measurable disease,&#xD;
             defined by at least one of the following:&#xD;
&#xD;
               1. Serum monoclonal protein ≥0.5 g/dL;&#xD;
&#xD;
               2. Monoclonal protein in the urine on 24-hour electrophoresis ≥200 mg;&#xD;
&#xD;
               3. Serum immunoglobulin free light chain (FLC) ≥10 mg/dL (100 mg/L) provided serum&#xD;
                  FLC ratio is abnormal;&#xD;
&#xD;
               4. New of progressing biopsy proven plasmacytoma on exam or imaging; or&#xD;
&#xD;
               5. Bone marrow plasma cells ≥20%;&#xD;
&#xD;
          5. Cycle 1 day 1 of study treatment must be within 3 months of last exposure to&#xD;
             Daratumumab.&#xD;
&#xD;
          6. Life expectancy &gt;3 months&#xD;
&#xD;
          7. ECOG PS 0-2&#xD;
&#xD;
          8. Age ≥18&#xD;
&#xD;
          9. Adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac&#xD;
             function based on the last assessment performed within the Screening Period, defined&#xD;
             as:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥1,000/μL;&#xD;
&#xD;
               2. Platelet count ≥50,000/μL, (≥30,000/μL if bone marrow plasma cells are ≥50% of&#xD;
                  cellularity);&#xD;
&#xD;
               3. Hemoglobin ≥7.5g/dL;&#xD;
&#xD;
               4. Creatinine clearance ≥60 mL/min (assessed as glomerular filtration rate using the&#xD;
                  Cockcroft-Gault formula);&#xD;
&#xD;
               5. Alanine aminotransferase or aspartate aminotransferase &lt;3 x upper limit of normal&#xD;
                  (ULN);&#xD;
&#xD;
               6. Total bilirubin &lt;2 x ULN (except for patients with Gilbert's syndrome confirmed&#xD;
                  by UGT1A1 mutation);&#xD;
&#xD;
               7. Left ventricular ejection fraction ≥50% as assessed by echocardiography or&#xD;
                  multi-gated acquisition (MUGA) scan; and&#xD;
&#xD;
               8. Must have a minimum level of pulmonary reserve defined as Grade &lt;2 dyspnea and&#xD;
                  pulse oxygenation ≥92% on room air;&#xD;
&#xD;
         10. Prior to first dose of study drug, a woman must be either:&#xD;
&#xD;
               -  Not of childbearing potential: premenarchal; postmenopausal (&gt;45 years of age&#xD;
                  with amenorrhea for at least 12 months or any age with amenorrhea for at least 6&#xD;
                  months and a serum follicle stimulating hormone level &gt;40 IU/L or mIU/mL]);&#xD;
                  permanently sterilized (eg, bilateral tubal occlusion [which includes tubal&#xD;
                  ligation procedures as consistent with local regulations], hysterectomy,&#xD;
                  bilateral salpingectomy, bilateral oophorectomy); or otherwise be incapable of&#xD;
                  pregnancy&#xD;
&#xD;
               -  Of childbearing potential and practicing a highly effective method of birth&#xD;
                  control for 4 weeks before initiating study treatment that is consistent with&#xD;
                  local regulations regarding the use of birth control methods for subjects&#xD;
                  participating in clinical studies: e.g., established use of oral, injected or&#xD;
                  implanted hormonal methods of contraception; placement of an intrauterine device&#xD;
                  or intrauterine system; barrier methods: condom with spermicidal&#xD;
                  foam/gel/film/cream/suppository or occlusive cap (diaphragm or cervical/vault&#xD;
                  caps) with spermicidal foam/gel/film/cream/suppository; male partner&#xD;
                  sterilization (the vasectomized partner should be the sole partner for that&#xD;
                  subject); true abstinence (when this is in line with the preferred and usual&#xD;
                  lifestyle of the subject) Note: If the childbearing potential changes after start&#xD;
                  of the study (e.g., woman who is not heterosexually active becomes active,&#xD;
                  premenarchal woman experiences menarche)&#xD;
&#xD;
               -  a woman must begin a highly effective method of birth control, as described&#xD;
                  above.&#xD;
&#xD;
         11. A woman of childbearing potential must have 2 negative serum (β human chorionic&#xD;
             gonadotropin) or urine pregnancy tests during screening, the first one within 28 days&#xD;
             prior to the first dose of study drug and the second within 24 hours prior to the&#xD;
             first dose of study drug.&#xD;
&#xD;
         12. A man who is sexually active with a woman of childbearing potential and has not had a&#xD;
             vasectomy must agree to use a barrier method of birth control e.g., either condom with&#xD;
             spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm&#xD;
             or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men&#xD;
             must also not donate sperm during the study and for 3 months after receiving the last&#xD;
             dose of study drug.&#xD;
&#xD;
         13. Subjects must be willing and able to adhere to the prohibitions and restrictions&#xD;
             specified in this protocol and referenced in the informed consent form (ICF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Major concurrent illness or organ dysfunction&#xD;
&#xD;
          2. Active GVHD requiring systemic corticosteroids in a subject who previously received&#xD;
             allogeneic-SCT.&#xD;
&#xD;
          3. Cord compression or CNS involvement&#xD;
&#xD;
          4. Recent/Prior active malignancy requiring active therapy 2 years prior to enrollment&#xD;
             excluding non-melanoma skin cancer.&#xD;
&#xD;
          5. Prior life-threatening hypersensitivity to daratumumab or an IMiD&#xD;
&#xD;
          6. Plasma cell leukemia&#xD;
&#xD;
          7. Pregnant or lactating females&#xD;
&#xD;
          8. Men donating sperm during study&#xD;
&#xD;
          9. Seropositive for human immunodeficiency virus (HIV)&#xD;
&#xD;
         10. Seropositive for hepatitis B (defined by a positive test for hepatitis B surface&#xD;
             antigen [HBsAg]). Subjects with resolved infection (ie, subjects who are HBsAg&#xD;
             negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or&#xD;
             antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time&#xD;
             polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels.&#xD;
             Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic&#xD;
             findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic&#xD;
             marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV&#xD;
             DNA by PCR&#xD;
&#xD;
         11. Seropositive for hepatitis C (except in the setting of a sustained virologic response&#xD;
             [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy)&#xD;
&#xD;
         12. Chronic obstructive pulmonary disease (COPD) with a Forced Expiratory Volume in 1&#xD;
             second (FEV1) less than 50% of predicted normal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noa Biran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hackensack Meridian Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Palka Anand</last_name>
    <phone>551-996-3040</phone>
    <email>Palka.Anand@hmhn.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristin Ivanovski</last_name>
    <phone>551-996-5231</phone>
    <email>Kristin.Ivanovski@hmhn.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Palka Anand</last_name>
      <phone>551-996-3040</phone>
      <email>Palka.Anand@hmhn.org</email>
    </contact>
    <contact_backup>
      <last_name>Kristin Ivanovski</last_name>
      <phone>551-996-5231</phone>
      <email>Kristin.Ivanovski@hmhn.org</email>
    </contact_backup>
    <investigator>
      <last_name>Noa Biran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29. Erratum in: Leukemia. 2012 May;26(5):1153. Nari, Hareth [corrected to Nahi, Hareth].</citation>
    <PMID>21799510</PMID>
  </reference>
  <reference>
    <citation>Lee HC. Structure and enzymatic functions of human CD38. Mol Med. 2006 Nov-Dec;12(11-12):317-23.</citation>
    <PMID>17380198</PMID>
  </reference>
  <reference>
    <citation>Chillemi A, Zaccarello G, Quarona V, Ferracin M, Ghimenti C, Massaia M, Horenstein AL, Malavasi F. Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule. Mol Med. 2013 May 20;19:99-108. doi: 10.2119/molmed.2013.00009. Review.</citation>
    <PMID>23615966</PMID>
  </reference>
  <reference>
    <citation>Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Oct 6;375(14):1319-1331.</citation>
    <PMID>27705267</PMID>
  </reference>
  <reference>
    <citation>Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21.</citation>
    <PMID>28637662</PMID>
  </reference>
  <reference>
    <citation>Nijhof IS, Groen RW, Lokhorst HM, van Kessel B, Bloem AC, van Velzen J, de Jong-Korlaar R, Yuan H, Noort WA, Klein SK, Martens AC, Doshi P, Sasser K, Mutis T, van de Donk NW. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015 Oct;29(10):2039-49. doi: 10.1038/leu.2015.123. Epub 2015 May 15.</citation>
    <PMID>25975191</PMID>
  </reference>
  <reference>
    <citation>Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Sasser AK, van de Donk NW. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15.</citation>
    <PMID>27307294</PMID>
  </reference>
  <reference>
    <citation>Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008 Aug 29;321(5893):1218-21. doi: 10.1126/science.1158799. Epub 2008 Jul 31.</citation>
    <PMID>18669821</PMID>
  </reference>
  <reference>
    <citation>Wichterle H, Lieberam I, Porter JA, Jessell TM. Directed differentiation of embryonic stem cells into motor neurons. Cell. 2002 Aug 9;110(3):385-97.</citation>
    <PMID>12176325</PMID>
  </reference>
  <reference>
    <citation>Collins SJ. The role of retinoids and retinoic acid receptors in normal hematopoiesis. Leukemia. 2002 Oct;16(10):1896-905. Review.</citation>
    <PMID>12357341</PMID>
  </reference>
  <reference>
    <citation>Kantarjian HM, Keating MJ, Walters RS, Estey EH, McCredie KB, Smith TL, Dalton WT Jr, Cork A, Trujillo JM, Freireich EJ. Acute promyelocytic leukemia. M.D. Anderson Hospital experience. Am J Med. 1986 May;80(5):789-97.</citation>
    <PMID>3458366</PMID>
  </reference>
  <reference>
    <citation>Cordonnier C, Vernant JP, Brun B, Heilmann MG, Kuentz M, Bierling P, Farcet JP, Rodet M, Duedari N, Imbert M, et al. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer. 1985 Jan 1;55(1):18-25.</citation>
    <PMID>3855265</PMID>
  </reference>
  <reference>
    <citation>Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood. 1992 Feb 1;79(3):543-53. Review.</citation>
    <PMID>1732003</PMID>
  </reference>
  <reference>
    <citation>Chomienne C, Ballerini P, Balitrand N, Daniel MT, Fenaux P, Castaigne S, Degos L. All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood. 1990 Nov 1;76(9):1710-7.</citation>
    <PMID>2224120</PMID>
  </reference>
  <reference>
    <citation>Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997 Oct 9;337(15):1021-8. Erratum in: N Engl J Med 1997 Nov 27;337(22):1639.</citation>
    <PMID>9321529</PMID>
  </reference>
  <reference>
    <citation>Ogata A, Nishimoto N, Shima Y, Yoshizaki K, Kishimoto T. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Blood. 1994 Nov 1;84(9):3040-6.</citation>
    <PMID>7949175</PMID>
  </reference>
  <reference>
    <citation>Siegel D, Niesvizky R, Miller WH Jr, Busquets X, Kumar R, MIchaeli J: All trans retinoic acid (ATRA) and interferon alfa (IFNa) synergistically inhibit myeloma cell growth and induce retinoic acid receptor alfa (RARa) expression. Blood 80:121a:1992 (abstr, supple 1).</citation>
  </reference>
  <reference>
    <citation>Musto P, Falcone A, Sajeva MR, D'Arena G, Bonini A, Carotenuto M. All-trans retinoic acid for advanced multiple myeloma. Blood. 1995 Jun 15;85(12):3769-70.</citation>
    <PMID>7780162</PMID>
  </reference>
  <reference>
    <citation>Frerichs KA et al, Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma: results of the Phase ½ Dara/Atra study. Blood (2019) 134 S:1:1826.</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

